Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics

Gracell Biotechnologies Inc. (GRCL): $10.25

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add GRCL to Watchlist
Sign Up

Industry: Beverages

Industry

B

Ranked

#23 of 35

in industry

GRCL Price/Volume Stats

Current price $10.25 52-week high $10.44
Prev. close $10.24 52-week low $1.40
Day low $10.17 Volume 6,417,100
Day high $10.28 Avg. volume 1,315,803
50-day MA $9.13 Dividend yield N/A
200-day MA $5.01 Market Cap 744.95M

GRCL Stock Price Chart Interactive Chart >


Gracell Biotechnologies Inc. (GRCL) Company Bio


Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.


GRCL Latest News Stream


Event/Time News Detail
Loading, please wait...

GRCL Latest Social Stream


Loading social stream, please wait...

View Full GRCL Social Stream

Latest GRCL News From Around the Web

Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls

Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls

Yahoo | December 27, 2023

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

Yahoo | December 27, 2023

These Stocks Moved the Most Today: RayzeBio, Gracell, NIO, Intel, Manchester United, FedEx, Arm, and More

RayzeBio surges after reaching an agreement to be acquired by Bristol Myers Squibb for $62.50 a share in cash, while Shanghai-based Gracell Biotechnologies is being bought by AstraZeneca in a deal valued at up to $1.2 billion.

Yahoo | December 26, 2023

US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in view

U.S. stocks extended their rally on Tuesday, kicking off the final week of 2023 with expectations that the Federal Reserve will begin cutting interest rates as soon as March. All three major U.S. stock indexes rose in light trading a day after the Christmas holiday, with the S&P 500 touching its highest intraday level since January 2022. On Friday, the three indexes notched their eighth straight weekly gains - their longest weekly winning streaks in years - as economic data indicated inflation is easing down closer to the Fed's average annual 2% target.

Yahoo | December 26, 2023

AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals

AstraZeneca announced Tuesday it would acquire Gracell Biotechnologies in a deal valued at up to $1.2 billion. Gracell is a Chinese biopharmaceutical company that focuses on cancer drug development. AstraZeneca said in a press release that it plans on buying the company to further its cell therapy ambitions.

Yahoo | December 26, 2023

Read More 'GRCL' Stories Here

GRCL Price Returns

1-mo N/A
3-mo 0.05%
6-mo 93.40%
1-year 330.67%
3-year -41.79%
5-year N/A
YTD 2.09%
2023 336.52%
2022 -61.92%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!